Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1764.75 Insider Own1.06% Shs Outstand0.83M Perf Week-20.20%
Market Cap3.25M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.83M Perf Month-22.57%
Income-105.53M PEG- EPS next Q-2.20 Inst Own11.47% Short Float2.28% Perf Quarter-37.54%
Sales0.00M P/S- EPS this Y99.32% Inst Trans- Short Ratio0.07 Perf Half Y-34.51%
Book/sh13.44 P/B0.29 EPS next Y- ROA-142.87% Short Interest0.02M Perf Year-94.88%
Cash/sh2.45 P/C1.60 EPS next 5Y- ROE-180.17% 52W Range3.41 - 79.80 Perf YTD-56.56%
Dividend Est.- P/FCF- EPS past 5Y- ROI-940.28% 52W High-95.10% Beta0.66
Dividend TTM- Quick Ratio0.30 Sales past 5Y0.00% Gross Margin- 52W Low14.66% ATR (14)0.62
Dividend Ex-Date- Current Ratio0.30 EPS Y/Y TTM-169.98% Oper. Margin0.00% RSI (14)44.25 Volatility17.35% 14.37%
Employees7 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price20.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q96.66% Payout- Rel Volume0.19 Prev Close3.88
Sales Surprise- EPS Surprise-22.43% Sales Q/Q- EarningsMay 15 BMO Avg Volume289.52K Price3.91
SMA20-6.15% SMA50-14.33% SMA200-70.21% Trades Volume54,136 Change0.77%
Jul-18-24 11:18AM
Jul-09-24 07:57AM
May-15-24 11:53PM
May-14-24 07:57AM
07:57AM Loading…
Apr-29-24 07:57AM
Apr-04-24 07:57AM
Mar-25-24 08:17AM
Mar-18-24 07:57AM
Mar-14-24 07:57AM
Feb-29-24 07:57AM
Feb-28-24 07:57AM
Feb-26-24 07:55AM
Feb-22-24 07:47AM
Feb-14-24 07:53AM
08:02AM Loading…
Feb-07-24 08:02AM
Jan-31-24 07:57AM
Jan-24-24 07:57AM
Jan-17-24 01:31PM
Jan-10-24 08:06AM
Jan-04-24 07:50AM
Jan-03-24 08:07AM
Dec-18-23 08:12AM
Dec-14-23 07:01AM
Dec-07-23 11:20AM
Dec-06-23 09:00PM
11:30AM Loading…
Nov-30-23 11:30AM
Nov-14-23 04:35PM
Nov-09-23 07:35AM
Nov-06-23 07:05AM
Nov-01-23 08:07AM
Oct-25-23 06:50AM
Oct-18-23 07:05AM
Oct-11-23 07:05AM
Oct-04-23 07:05AM
Sep-27-23 07:07AM
Sep-22-23 06:35AM
Sep-12-23 06:30AM
Aug-21-23 04:15PM
Jul-24-23 08:00AM
Jul-17-23 07:38AM
Jul-14-23 07:37AM
Jul-10-23 07:37AM
Jul-07-23 07:37AM
Jun-28-23 07:37AM
Jun-20-23 04:07PM
Jun-13-23 08:07AM
Jun-06-23 09:07AM
May-25-23 09:07AM
May-19-23 04:15PM
May-15-23 09:07AM
May-12-23 09:07AM
May-11-23 09:07AM
May-09-23 09:05AM
May-04-23 09:07AM
May-01-23 06:30PM
Apr-27-23 09:07AM
Apr-26-23 09:10AM
Apr-25-23 09:07AM
Apr-24-23 09:07AM
Apr-19-23 09:07AM
Apr-13-23 09:07AM
Apr-12-23 09:07AM
Apr-11-23 09:07AM
Apr-10-23 09:07AM
Apr-03-23 09:05AM
Mar-13-23 04:30PM
Mar-07-23 09:20AM
Mar-01-23 09:20AM
Feb-27-23 09:20AM
Feb-23-23 09:20AM
Jan-27-23 04:00PM
Jan-25-23 09:45AM
Jan-11-23 02:45PM
Jan-05-23 09:45AM
Jan-03-23 09:45AM
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.